These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 9143283)

  • 21. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus.
    Hammond SA; Cook SJ; Falo LD; Issel CJ; Montelaro RC
    Virology; 1999 Feb; 254(1):37-49. PubMed ID: 9927572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.
    McGuire TC; Tumas DB; Byrne KM; Hines MT; Leib SR; Brassfield AL; O'Rourke KI; Perryman LE
    J Virol; 1994 Mar; 68(3):1459-67. PubMed ID: 8107209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors.
    Lonning SM; Zhang W; Leib SR; McGuire TC
    J Virol; 1999 Apr; 73(4):2762-9. PubMed ID: 10074123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection.
    Rwambo PM; Issel CJ; Adams WV; Hussain KA; Miller M; Montelaro RC
    Arch Virol; 1990; 111(3-4):199-212. PubMed ID: 2162160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine.
    Ma J; Jiang C; Lin Y; Wang X; Zhao L; Xiang W; Shao Y; Shen R; Kong X; Zhou J
    Arch Virol; 2009; 154(5):867-73. PubMed ID: 19363668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies.
    Grund CH; Lechman ER; Pezzuolo NA; Issel CJ; Montelaro RC
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():435-42. PubMed ID: 8601778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.
    Howe L; Leroux C; Issel CJ; Montelaro RC
    J Virol; 2002 Nov; 76(21):10588-97. PubMed ID: 12368301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement.
    Raabe ML; Issel CJ; Cook SJ; Cook RF; Woodson B; Montelaro RC
    Virology; 1998 May; 245(1):151-62. PubMed ID: 9614876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.
    Tallmadge RL; Brindley MA; Salmans J; Mealey RH; Maury W; Carpenter S
    Clin Vaccine Immunol; 2008 Jul; 15(7):1138-40. PubMed ID: 18448619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein.
    Wang SZ; Rushlow KE; Issel CJ; Cook RF; Cook SJ; Raabe ML; Chong YH; Costa L; Montelaro RC
    Virology; 1994 Feb; 199(1):247-51. PubMed ID: 8116252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serologically silent, occult equine infectious anemia virus (EIAV) infections in horses.
    Ricotti S; Garcia MI; Veaute C; Bailat A; Lucca E; Cook RF; Cook SJ; Soutullo A
    Vet Microbiol; 2016 May; 187():41-49. PubMed ID: 27066707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus.
    Tagmyer TL; Craigo JK; Cook SJ; Issel CJ; Montelaro RC
    J Gen Virol; 2007 Apr; 88(Pt 4):1324-1336. PubMed ID: 17374779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain.
    Howe L; Craigo JK; Issel CJ; Montelaro RC
    J Gen Virol; 2005 Jan; 86(Pt 1):139-149. PubMed ID: 15604441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-neutralizing and subclass characteristics of antibody from horses with equine infectious anemia virus.
    O'Rourke KI; Perryman LE; McGuire TC
    Vet Immunol Immunopathol; 1989 Nov; 23(1-2):41-9. PubMed ID: 2559537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies.
    Liu C; Cook FR; Cook SJ; Craigo JK; Even DL; Issel CJ; Montelaro RC; Horohov DW
    Vet Immunol Immunopathol; 2012 Aug; 148(3-4):302-10. PubMed ID: 22795699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equine infectious anemia: prospects for control.
    Issel CJ; McManus JM; Hagius SD; Foil LD; Adams WV; Montelaro RC
    Dev Biol Stand; 1990; 72():49-57. PubMed ID: 2178130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses.
    Jin S; Issel CJ; Montelaro RC
    Clin Diagn Lab Immunol; 2004 Nov; 11(6):1120-9. PubMed ID: 15539516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunology of a persistent retrovirus infection--equine infectious anemia.
    McGuire TC; Crawford TB
    Adv Vet Sci Comp Med; 1979; 23():137-59. PubMed ID: 95154
    [No Abstract]   [Full Text] [Related]  

  • 39. Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes.
    Mealey RH; Sharif A; Ellis SA; Littke MH; Leib SR; McGuire TC
    Virology; 2005 Aug; 339(1):110-26. PubMed ID: 15979679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.
    Hammond SA; Li F; McKeon BM; Cook SJ; Issel CJ; Montelaro RC
    J Virol; 2000 Jul; 74(13):5968-81. PubMed ID: 10846078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.